Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
Sell
-9,457
Closed -$477K 85
2016
Q1
$477K Buy
9,457
+27
+0.3% +$1.32K 0.01% 74
2015
Q4
$475K Sell
9,430
-19,631
-68% -$990K 0.01% 75
2015
Q3
$1.37M Sell
29,061
-1,741
-6% -$92.5K 0.02% 69
2015
Q2
$1.67M Sell
30,802
-866
-3% -$48.6K 0.03% 70
2015
Q1
$1.74M Sell
31,668
-703
-2% -$39.8K 0.03% 72
2014
Q4
$1.75M Sell
32,371
-440
-1% -$24.5K 0.03% 72
2014
Q3
$0 Buy
32,811
+1,240
+4% +$69.6K ﹤0.01% 144
2014
Q2
$1.74M Buy
31,571
+119
+0.4% +$6.49K 0.04% 68
2014
Q1
$1.7M Sell
31,452
-1
-0% -$52 0.04% 71
2013
Q4
$1.5M Buy
31,453
+218
+0.7% +$9.96K 0.04% 76
2013
Q3
$1.42M Sell
31,235
-1,170
-4% -$53.4K 0.05% 79
2013
Q2
$1.44M Buy
+32,405
New +$1.45M 0.06% 85

Other funds holding MRK

Thomaspartners's MRK Position: Q2 2016 in Review

Thomaspartners sold out of Merck (MRK) in Q2 2016, closing a stake of 9,457 shares — an estimated $477K sold.

Thomaspartners first reported a position in MRK in Q2 2013 and held it in 12 quarters. The position peaked at $1.75M in Q4 2014. 1,761 funds tracked by Wall St. Rank hold MRK as of Q2 2016.

  • Thomaspartners reported no remaining Merck position as of Q2 2016 after selling out during the quarter.
  • Thomaspartners sold 9,457 Merck shares in Q2 2016, an estimated $477K.
  • Thomaspartners first reported a position in Merck in Q2 2013 and held it in 12 quarters.
  • Thomaspartners's Merck position peaked at $1.75M in Q4 2014.
  • 1,761 funds tracked by Wall St. Rank held Merck as of Q2 2016.

Based on Thomaspartners's 13F filing for Q2 2016, filed 9 Aug 2016.